JUND (Ab-255) Antibody

What is the JUND (Ab-255) Antibody and what epitope does it recognize?

The JUND (Ab-255) Antibody is a polyclonal antibody raised in rabbits that specifically recognizes the human JunD proto-oncogene, which functions as an AP-1 transcription factor subunit. It was generated against a synthesized non-phosphopeptide derived from human JunD around the phosphorylation site of serine 255 (G-E-SP-P-P) . This antibody targets a specific epitope in the JunD protein that includes the serine-255 residue, making it particularly useful for studying JunD phosphorylation status and related signaling pathways .

What applications is the JUND (Ab-255) Antibody validated for?

The JUND (Ab-255) Antibody has been validated for multiple research applications including:

• Western Blot (WB): Recommended dilution of 1:500-1:1000

• Immunohistochemistry (IHC): Recommended dilution of 1:50-1:100

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Immunofluorescence (IF)

These validations make it versatile for protein expression studies, localization analyses, and protein-protein interaction investigations .

What species reactivity has been confirmed for this antibody?

According to the manufacturer's documentation, the JUND (Ab-255) Antibody has confirmed reactivity with:

• Human JunD (primary target)

• Mouse JunD

• Rat JunD

This cross-species reactivity has been verified through Western blot analysis of extracts from human cell lines including HT29 and 293 cells . The conservation of the epitope sequence across these species allows for comparative studies across different experimental models.

How is the JUND (Ab-255) Antibody purified and formulated?

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using the epitope-specific immunogen . This purification method ensures high specificity for the target epitope. The antibody is supplied in liquid formulation at a concentration of 1μg/μl. For optimal performance and longevity, the antibody should be stored at -20°C or -80°C as recommended by the manufacturer .

How can I optimize Western blot protocols for JUND (Ab-255) Antibody detection of phosphorylated versus non-phosphorylated states?

Optimizing Western blot protocols for distinguishing phosphorylated and non-phosphorylated JunD states requires careful consideration of sample preparation and experimental controls:

Methodological Approach:

• Sample Preparation: Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in your lysis buffer when studying phosphorylated states.

• Controls: Run parallel samples with and without phosphatase treatment to verify phosphorylation-specific bands.

• Blocking Strategy: Use 5% BSA in TBST rather than milk for phospho-specific detection, as milk contains phosphoproteins that can interfere with detection.

• SDS-PAGE Conditions: Consider using Phos-tag™ acrylamide gels for enhanced separation of phosphorylated proteins.

• Dilution Optimization: Start with the recommended 1:500 dilution and titrate if necessary based on signal-to-noise ratio.

• Validation: Confirm specificity by using phospho-mimetic (S255E) and phospho-deficient (S255A) JunD constructs as controls .

What considerations should be made when designing immunoprecipitation experiments with JUND (Ab-255) Antibody?

Methodological Considerations:

• Antibody Amount: Typically 2-5μg of JUND (Ab-255) Antibody per 500μg of total protein lysate is recommended.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Cross-linking Option: Consider cross-linking the antibody to beads using dimethyl pimelimidate (DMP) to prevent antibody co-elution.

• Elution Strategy: Use either acidic elution (pH 2.5-3.0) followed by immediate neutralization, or specific elution with the immunizing peptide.

• Controls: Always include an isotype control (rabbit IgG) processed identically to identify non-specific interactions.

• Verification: Confirm results with reverse immunoprecipitation using antibodies against suspected interacting partners .

How can I apply JUND (Ab-255) Antibody in chromatin immunoprecipitation (ChIP) studies?

While not explicitly validated for ChIP in the provided documentation, polyclonal antibodies against transcription factors are frequently used in ChIP applications. For adapting JUND (Ab-255) Antibody to ChIP:

Methodological Approach:

• Crosslinking: Use 1% formaldehyde for 10 minutes at room temperature.

• Sonication: Optimize sonication conditions to generate DNA fragments of 200-500bp.

• Antibody Amount: Start with 5μg of antibody per ChIP reaction.

• Incubation: Perform overnight incubation at 4°C with rotation.

• Beads Selection: Use protein A beads which have higher affinity for rabbit IgG.

• Washing: Perform stringent washing to reduce background.

• Elution and Reversal: Elute chromatin and reverse crosslinks at 65°C for 4-6 hours.

• Controls: Include input DNA, IgG control, and positive control (antibody against a known JunD-associated factor).

• Validation: Confirm enrichment at known JunD binding sites using qPCR before proceeding to ChIP-seq .

How can I address non-specific binding when using JUND (Ab-255) Antibody in Western blots?

Non-specific binding is a common challenge with antibodies, including JUND (Ab-255) Antibody. Here's a methodological approach to troubleshooting:

Methodological Approach:

• Increase Blocking Time/Concentration: Try 5% BSA or milk in TBST and increase blocking time to 2 hours.

• Optimize Antibody Dilution: Test a range of dilutions from 1:250 to 1:2000 to find optimal signal-to-noise ratio.

• Add Detergent: Increase Tween-20 concentration in wash buffer to 0.1-0.3%.

• Validate Specificity: Use JunD knockout/knockdown samples as negative controls.

• Peptide Competition: Pre-incubate antibody with excess immunizing peptide (G-E-SP-P-P) to confirm specificity.

• Adjust Exposure Time: Shorter exposure times may reveal true signal before non-specific bands appear.

• Alternative Blocking Agents: Consider specialized blocking agents like Odyssey blocking buffer for fluorescent detection systems .

What are potential interfering factors when studying JunD phosphorylation status using this antibody?

When investigating JunD phosphorylation, several factors may interfere with accurate detection:

Methodological Considerations:

• Phosphatase Activity: Endogenous phosphatases can dephosphorylate JunD during sample preparation. Use phosphatase inhibitor cocktails containing sodium orthovanadate, sodium fluoride, and β-glycerophosphate.

• Sample Handling: Keep samples on ice and process quickly to minimize dephosphorylation.

• Cell Stimulation Conditions: Optimize stimulation time and dose to capture peak phosphorylation.

• Cross-reactivity with Other JUN Family Members: JunD shares homology with c-Jun and JunB. Verify specificity through siRNA knockdown of specific family members.

• Antibody Specificity: Since this antibody recognizes the region around Ser255, modifications to adjacent amino acids might affect recognition.

• Detection Method Selection: Consider using Phos-tag gels for enhanced separation of phosphorylated species.

• Data Validation: Combine results with additional techniques such as mass spectrometry to confirm phosphorylation status .

How should I interpret contradictory results between JUND (Ab-255) Antibody and other JunD antibodies?

Contradictory results between different antibodies targeting the same protein are not uncommon and require careful analysis:

Methodological Approach to Resolution:

• Epitope Mapping: Compare the epitopes recognized by different antibodies. JUND (Ab-255) targets the region around Ser255, while other antibodies may target N or C-terminal regions.

• Phosphorylation Interference: If other antibodies recognize regions affected by phosphorylation state, results may differ based on cellular conditions.

• Isoform Recognition: Determine if antibodies differentially recognize JunD isoforms resulting from alternative translation initiation sites.

• Validation Controls: Test antibodies against overexpressed wildtype JunD and mutant constructs.

• Protein Complexes: JunD functions in complexes that might mask epitopes differentially.

• Methodological Differences: Compare results across multiple techniques (WB, IP, IHC) to identify method-specific discrepancies.

• Peptide Competition: Conduct parallel peptide competition assays with each antibody to confirm specificity .

How does the specificity and sensitivity of JUND (Ab-255) Antibody compare to monoclonal antibodies against JunD?

Comparative Analysis:

The polyclonal nature of JUND (Ab-255) Antibody provides advantages in detecting native proteins across multiple applications, but monoclonals may offer superior reproducibility for standardized assays. For critical experiments, validation with both antibody types is recommended for comprehensive analysis .

How can JUND (Ab-255) Antibody be integrated into multiplexed immunoassays?

Multiplexed immunoassays allow simultaneous detection of multiple proteins and modification states:

Methodological Integration Approach:

• Antibody Conjugation: Consider direct conjugation to fluorophores for multiplexed immunofluorescence.

• Panel Design: Pair with antibodies against other AP-1 family members (c-Jun, JunB, c-Fos) using species-distinct primary antibodies.

• Sequential Immunodetection: For Western blots, use sequential probing with stripping between antibodies.

• Validation: Verify that signal stripping is complete between rounds of detection.

• Spectral Separation: Ensure fluorophores have sufficient spectral separation for accurate discrimination.

• Controls: Include single-stained controls to establish bleed-through parameters.

• Mass Cytometry Option: Consider conjugation to metal isotopes for mass cytometry (CyTOF) applications for highly multiplexed detection.

• Data Analysis: Apply appropriate compensation algorithms when analyzing multiplexed data .

What considerations should be made when developing quantitative assays using JUND (Ab-255) Antibody?

Development of quantitative assays requires careful optimization and validation:

Methodological Development Approach:

• Standard Curve Generation: Create a standard curve using recombinant JunD protein or cell lysates with known JunD expression levels.

• Linear Range Determination: Establish the linear range of detection through serial dilutions.

• Internal Controls: Incorporate housekeeping proteins (β-actin, GAPDH) for normalization.

• Technical Replicates: Perform at least triplicate measurements for each sample.

• Intra-assay Variation: Calculate coefficient of variation (CV) between technical replicates (aim for <15%).

• Inter-assay Variation: Include standard samples across different experiment days to assess reproducibility.

• Phosphorylation-specific Quantification: For phospho-specific studies, normalize phospho-JunD signal to total JunD levels.

• Statistical Analysis: Apply appropriate statistical tests based on data distribution and experimental design .

How can I utilize computational modeling to better understand the binding characteristics of JUND (Ab-255) Antibody?

Computational approaches can provide insights into antibody-antigen interactions:

Methodological Approach:

• Epitope Modeling: Use tools like IEDB Epitope Analysis Resource to predict antibody binding sites based on the immunizing peptide sequence (G-E-SP-P-P).

• Homology Modeling: Generate structural models of the antibody variable regions using platforms like AbPredict or PIGS server.

• Molecular Docking: Perform docking simulations between the modeled antibody and JunD epitope using tools like Rosetta or AutoDock.

• Molecular Dynamics Simulations: Run MD simulations to assess the stability of the antibody-antigen complex.

• Binding Affinity Prediction: Calculate theoretical binding affinities using MM-PBSA or MM-GBSA approaches.

• Cross-reactivity Analysis: Evaluate potential cross-reactivity with other Jun family members through sequence alignment and structural superimposition.

• Validation: Compare computational predictions with experimental binding data.

• Optimization: Use insights to design experiments that could enhance specificity or sensitivity .

How might JUND (Ab-255) Antibody be adapted for use in emerging single-cell protein analysis techniques?

Single-cell protein analysis represents a frontier in cellular biology research:

Methodological Adaptation Strategies:

• Microfluidic Antibody Capture: Optimize antibody concentration for microfluidic-based single-cell Western blots.

• Mass Cytometry Integration: Conjugate with rare earth metals for CyTOF analysis of JunD expression across heterogeneous cell populations.

• Proximity Ligation Assay (PLA) Application: Combine with antibodies against JunD binding partners to visualize protein interactions at single-cell resolution.

• CODEX Multiplexed Imaging: Incorporate into CODEX (CO-Detection by indEXing) panels for highly multiplexed tissue imaging.

• Antibody Validation: Verify specificity using JunD knockout controls in single-cell formats.

• Signal Amplification: Explore tyramide signal amplification for enhanced detection sensitivity in limited sample contexts.

• Quantification Standards: Develop calibration methods for absolute quantification in single-cell applications .

What considerations should be made when applying JUND (Ab-255) Antibody in studies of post-translational modification crosstalk?

JunD activity is regulated by multiple post-translational modifications that may interact functionally:

Methodological Considerations:

• Sequential Immunoprecipitation: Use JUND (Ab-255) Antibody for initial IP followed by probing with antibodies against other modifications (phosphorylation, acetylation, SUMOylation).

• Modification-specific Enrichment: Combine with phospho-enrichment techniques prior to immunoblotting.

• Site-directed Mutagenesis: Create JunD mutants with modified Ser255 and other PTM sites to evaluate interdependence.

• Inhibitor Studies: Apply kinase/phosphatase inhibitors to manipulate phosphorylation status while monitoring other modifications.

• Mass Spectrometry Integration: Use IP with JUND (Ab-255) Antibody followed by MS to identify co-occurring modifications.

• Temporal Analysis: Track multiple modifications across stimulation time courses to establish sequential relationships.

• Spatial Correlation: Apply multiplexed immunofluorescence to correlate different modifications within cellular compartments .

How can JUND (Ab-255) Antibody be utilized in the development of proximity-dependent labeling approaches?

Proximity-dependent labeling can reveal transient and stable protein interactions:

Methodological Implementation:

• BioID Fusion Constructs: Combine with BioID or TurboID proximity labeling by creating JunD fusion constructs.

• Validation: Use JUND (Ab-255) Antibody to confirm expression and proper localization of fusion proteins.

• APEX2 Alternative: Apply APEX2 peroxidase-mediated proximity labeling for subcellular specificity.

• Control Design: Create phospho-mimetic (S255D/E) and phospho-deficient (S255A) versions to identify phosphorylation-dependent interactions.

• Data Analysis: Compare interactomes from different cellular conditions using quantitative proteomics.

• Visualization: Combine with super-resolution microscopy to spatially resolve interaction networks.

• Functional Validation: Confirm key interactions using traditional co-IP with JUND (Ab-255) Antibody .

What are the methodological considerations for using JUND (Ab-255) Antibody in primary tissue samples and patient-derived materials?

Working with primary tissues introduces additional complexities:

Methodological Approach:

• Fixation Optimization: Test multiple fixation protocols (formalin, methanol, acetone) to determine optimal epitope preservation.

• Antigen Retrieval: Systematically evaluate heat-induced epitope retrieval methods (citrate buffer pH 6.0, EDTA buffer pH 9.0).

• Signal Amplification: Consider tyramide signal amplification or polymer detection systems for low abundance targets.

• Background Reduction: Implement additional blocking steps with animal serum matching secondary antibody species.

• Validation: Use tissues from JunD knockout models as negative controls when available.

• Sectioning Considerations: Optimize section thickness (typically 3-5μm for IHC, 8-10μm for IF).

• Quantification: Develop reproducible scoring systems for semi-quantitative analysis or use digital image analysis for quantification.

• Clinical Correlation: Correlate JunD expression/phosphorylation with patient outcomes or treatment responses .

How can I apply JUND (Ab-255) Antibody in live-cell imaging applications?

While challenging due to the intracellular nature of JunD, live-cell applications may be possible:

Methodological Strategies:

• Antibody Fragments: Consider generating Fab or scFv fragments with maintained specificity.

• Cell Permeabilization: Use gentle permeabilization methods like saponin or Streptolysin O for transient pore formation.

• Antibody Delivery: Explore microinjection, electroporation, or cell-penetrating peptide conjugation.

• Fluorophore Selection: Choose photostable fluorophores with minimal phototoxicity (e.g., Alexa 488, JF dyes).

• Alternative Approaches: Consider genetically encoded sensors that respond to JunD activity as complementary approaches.

• Controls: Include non-targeting antibody fragments to control for non-specific effects.

• Validation: Verify that antibody binding doesn't disrupt normal JunD function or localization.

• Physiological Conditions: Maintain physiological temperature and pH during imaging .

What considerations should be made when developing an antibody-drug conjugate (ADC) with JUND (Ab-255) Antibody for research applications?

While primarily for research rather than therapeutic use, ADC approaches can provide functional insights:

Methodological Development Considerations:

• Target Validation: Confirm JunD expression levels and subcellular localization in target versus non-target cells.

• Conjugation Chemistry: Select site-specific conjugation methods to preserve antibody binding activity.

• Linker Selection: Consider cleavable linkers for intracellular release of payload after internalization.

• Payload Selection: Choose between fluorophores (for tracking) or cytotoxic agents (for functional studies).

• Drug-to-Antibody Ratio: Optimize the number of payload molecules per antibody (typically 2-4).

• Characterization: Verify conjugate homogeneity using mass spectrometry and size-exclusion chromatography.

• Functional Validation: Confirm that conjugation doesn't impair antibody binding affinity or specificity.

• Controls: Include non-targeting antibody conjugates with identical drug-to-antibody ratios .